Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CTX-320 by CRISPR Therapeutics for Atherosclerosis: Likelihood of Approval
CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I...